Stemness characteristics of fibrolamellar hepatocellular carcinoma: Immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma

Annals of Clinical and Laboratory Science

Volumn 40, Issue 2, 2010, Pages 126-134

  Zenali, Maryam J ^a   Tan, Dongfeng ^b   Li, Wei ^a   Dhingra, Sadhna ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Beta catenin; Cancer stem cells; CD133; CD44; Fibrolamellar hepatocellular carcinoma; Ki 67; PPAR gamma; Skp2

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; HERMES ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANTIGEN EXPRESSION; ARTICLE; CANCER STEM CELL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER PARENCHYMA; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, CD44; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; GLYCOPROTEINS; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; PPAR GAMMA; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 77951735538     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956;91:168-186.
2. Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, Meyer T. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol 2009;35:617-621.
3. Meriggi F, Forni E. Surgical therapy of hepatic fibrolamellar carcinoma. Ann Ital Chir 2007;78:53-58.
4. Moreno-Luna LE, Arrieta O, García-Leiva J, Martínez B, Torre A, Uribe M, León-Rodríguez E. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer 2005;5:142. (Pubitemid 41631789)
5. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004;39:798-803. (Pubitemid 38337660)
6. Kanai T, Takabayashi T, Kawano Y, Kuramochi S, Miyazawa N. A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol 2004;34:346-351. (Pubitemid 43115317)
7. Sakariassen PO, Immervoll H, Chekenya M. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 2007;9:882-892. (Pubitemid 350086444)
8. Hill RP, Perris R. "Destemming" cancer stem cells. J Natl Cancer Inst 2007;99:1435-1440.
9. Alison MR, Murphy G, Leedham S. Stem cells and cancer: a deadly mix. Cell Tissue Res 2008;331:109-124. (Pubitemid 350265500)
10. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med 2009;133:568-579.
11. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284. (Pubitemid 40488633)
12. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556. (Pubitemid 46890873)
13. Matsumoto K, Yasui K, Yamashita N, Horie Y, Yamada T, Tani Y, Shibata H, Nakano T. In vitro proliferation potential of AC133 positive cells in peripheral blood. Stem Cells 2000;18:196-203.
14. Yasuda M, Nakano K, Yasumoto K, Tanaka Y. CD44: functional relevance to inflammation and malignancy. Histol Histopathol 2002;17:945-950. (Pubitemid 34784678)
15. Sasaki K, Kon J, Mizuguchi T, Chen Q, Ooe H, Oshima H, Hirata K, Mitaka T. Proliferation of hepatocyte progenitor cells isolated from adult human livers in serum-free medium. Cell Transplant 2008;17:1221-1230.
16. Rountree CD, Ding W, He L, Stiles B. Expansion of CD 133 expressing liver cancer stem cells in liver specifie PTEN deleted mice. Stem Cells 2009;27:290-299.
17. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP. Liver stem cells and hepatocellular carcinoma. Hepatology 2009;49:318-329.
18. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007;120:1444-1450. (Pubitemid 46355378)
19. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008;62:1212-1218. (Pubitemid 351977611)
20. Salnikov AV, Kusumawidjaja G, Rausch V, Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM, Moldenhauer G, Büchler MW, Schemmer P, Herr I. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 2009;275:185-193.
21. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G. CD133 antigen expression in ovarian cancer. BMC Cancer 2009;9:221.
22. Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002;160:1457-1466. (Pubitemid 34411648)
23. Dhingra S, Li W, Tan D, Zenali M, Brown RE. Morphoproteomics defines the cell cycle biology of fibrolamellar hepatocellular carcinoma. Submitted for publication.
24. Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004;130:73-79. (Pubitemid 38316669)
25. Wu XZ, Chen D. Origin of hepatocellular carcinoma: role of stem cells. J Gastroenterol Hepatol 2006;21:1093-1098. (Pubitemid 43909997)
26. Zhang A, London R, Schulz FM, Giguère-Simmonds PW, Delriviere L, Chandraratana H, Hardy K, Zheng S, Olynyk JK, Yeoh G. Human liver progenitor cell lines are readily established from non-tumorous tissue adjacent to hepatocellular carcinoma. Stem Cells Dev October 2009 [e-pub in advance of print].
27. Matsumoto Y, Motoki T, Kubota S, Takigawa M, Tsubouchi H, Gohda E. Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid. Biochem Biophys Res Commun 2008;366:110-116. (Pubitemid 350297221)
28. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J 2007;21:3777-3785. (Pubitemid 350232335)